Evotec (EVO) Expected to Release Quarterly Earnings on Thursday

Evotec (NASDAQ:EVO) will likely be announcing its Q3 2026 results before the market opens on Thursday, November 5th. Analysts expect Evotec to announce earnings of ($0.1988) per share and revenue of $154.63 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 8:00 AM ET.

Evotec Trading Up 2.2%

EVO opened at $1.60 on Thursday. Evotec has a fifty-two week low of $1.33 and a fifty-two week high of $4.19. The company has a quick ratio of 2.21, a current ratio of 2.33 and a debt-to-equity ratio of 0.62. The company has a fifty day moving average of $1.66 and a two-hundred day moving average of $2.55.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the stock. Berenberg Bank lowered shares of Evotec from a “buy” rating to a “hold” rating in a research note on Thursday, July 16th. TD Cowen cut Evotec from a “buy” rating to a “hold” rating and set a $2.00 target price on the stock. in a research report on Wednesday, July 15th. Weiss Ratings lowered Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 25th. Finally, HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Evotec in a research note on Wednesday, October 14th. One analyst has rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $3.00.

Evotec Company Profile

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic research organizations. The company combines scientific expertise, proprietary technologies and integrated research platforms to identify and advance potential medicines across multiple therapeutic areas, including neuroscience, oncology, metabolic disease, infectious disease and inflammation.

Evotec’s activities span early-stage target identification, compound screening, medicinal chemistry, pharmacology, preclinical research and selected clinical development services.